|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clini. 68:7–30. 2018. View Article : Google Scholar
|
|
3
|
Tuan J and Chen YX: Dietary and lifestyle
factors associated with colorectal cancer risk and interactions
with microbiota: Fiber, red or processed meat and alcoholic drinks.
Gastrointest Tumors. 3:17–24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laohavinij S, Maneechavakajorn J and
Techatanol P: Prognostic factors for survival in colorectal cancer
patients. J Med Assoc Thai. 93:1156–1166. 2010.PubMed/NCBI
|
|
5
|
Hansen IO and Jess P: Possible better
long-term survival in left versus right-sided colon cancer - A
systematic review. Dan Med J. 59:A44442012.PubMed/NCBI
|
|
6
|
Wray CM, Ziogas A, Hinojosa MW, Le H,
Stamos MJ and Zell JA: Tumor subsite location within the colon is
prognostic for survival after colon cancer diagnosis. Dis Colon
Rectum. 52:1359–1366. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Benedix F, Kube R, Meyer F, Schmid U,
Gastinger I and Lippert H; Colon/Rectum Carcinomas and (Primary
Tumor) Study Group, : Comparison of 17,641 patients with right- and
left-sided colon cancer: Differences in epidemiology, perioperative
course, histology, and survival. Dis Colon Rectum. 53:57–64. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hutchins G, Southward K, Handley K, Magill
L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M,
Kerr D, et al: Value of mismatch repair, KRAS, and
BRAF mutations in predicting recurrence and benefits from
chemotherapy in colorectal cancer. J Clini Oncol. 29:1261–1270.
2011. View Article : Google Scholar
|
|
9
|
Elnatan J, Goh HS and Smith DR:
C-KI-RAS activation and the biological behaviour of proximal
and distal colonic adenocarcinomas. Eur J Cancer 32A. 491–497.
1996. View Article : Google Scholar
|
|
10
|
Babuke T and Tikkanen R: Dissecting the
molecular function of reggie/flotillin proteins. Eur J Cell Biol.
86:525–532. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Langhorst MF, Reuter A and Stuermer CA:
Scaffolding microdomains and beyond: The function of
reggie/flotillin proteins. Cell Mol Life Sci. 62:2228–2240. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Winship AL, Rainczuk K and Dimitriadis E:
Flotillin-1 protein is upregulated in human endometrial cancer and
localization shifts from epithelial to stromal with increasing
tumor grade. Cancer Investigat. 34:26–31. 2016. View Article : Google Scholar
|
|
13
|
Yang FQ, Zhang HM, Chen SJ, Yan Y and
Zheng JH: MiR-506 is down-regulated in clear cell renal cell
carcinoma and inhibits cell growth and metastasis via targeting
FLOT1. PLoS One. 10:e01202582015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guan Y, Song H, Zhang G and Ai X:
Overexpression of flotillin-1 is involved in proliferation and
recurrence of bladder transitional cell carcinoma. Oncol Rep.
32:748–754. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Zhang Y, Chen SW, Li FJ, Zhuang SM,
Wang LP, Zhang J and Song M: Prognostic significance of Flotillin1
expression in clinically N0 tongue squamous cell cancer. Int J
Clini Exp Pathol. 7:996–1003. 2014.
|
|
16
|
Gao W, Xu J, Wang F, Zhang L, Peng R, Shu
Y, Wu J, Tang Q and Zhu Y: Plasma membrane proteomic analysis of
human gastric cancer tissues: Revealing flotillin 1 as a marker for
gastric cancer. BMC Cancer. 15:3672015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li L, Luo J, Wang B, Wang D, Xie X, Yuan
L, Guo J, Xi S, Gao J, Lin X, et al: Microrna-124 targets
flotillin-1 to regulate proliferation and migration in breast
cancer. Mol Cancer. 12:1632013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arkhipova KA, Sheyderman AN, Laktionov KK,
Mochalnikova VV and Zborovskaya IB: Simultaneous expression of
flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell
lung cancer and soft tissue sarcomas. BMC Cancer. 14:1002014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Z, Yang Y, Gao Y, Wu X, Yang X, Zhu Y,
Yang H, Wu L, Yang C and Song L: Elevated expression of flotillin-1
is associated with lymph node metastasis and poor prognosis in
early-stage cervical cancer. Ameri J Cancer Res. 6:38–50. 2015.
|
|
20
|
Zhang SH, Wang CJ, Shi L, Li XH, Zhou J,
Song LB and Liao WT: High expression of FLOT1 is associated with
progression and poor prognosis in hepatocellular carcinoma. PLoS
One. 8:e647092013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gomez V, Sese M, Santamaria A, Martínez
JD, Castellanos E, Soler M, Thomson TM and Paciucci R: Regulation
of aurora B kinase by the lipid raft protein flotillin-1. J
Biological Chem. 285:20683–20690. 2010. View Article : Google Scholar
|
|
22
|
Ou YX, Liu FT, Chen FY and Zhu ZM:
Prognostic value of Flotillin-1 expression in patients with solid
tumors. Oncotarget. 8:52665–52677. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SH, Ha TK and Kwon SJ: Evaluation of
the 7th AJCC TNM staging system in point of lymph node
classification. J Gastric Cancer. 11:94–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thorn CC, Freeman TC, Scott N, Guillou PJ
and Jayne DG: Laser microdissection expression profiling of
marginal edges of colorectal tumours reveals evidence of increased
lactate metabolism in the aggressive phenotype. Gut. 58:404–412.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Niu Y, Shao Z, Wang H, Yang J, Zhang F,
Luo Y, Xu L, Ding Y and Zhao L: LASP1-S100A11 axis promotes
colorectal cancer aggressiveness by modulating TGFβ/Smad signaling.
Sci Rep. 6:261122016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pust S, Klokk TI, Musa N, Jenstad M,
Risberg B, Erikstein B, Tcatchoff L, Liestøl K, Danielsen HE, van
Deurs B, et al: Flotillins as regulators of ErbB2 levels in breast
cancer. Oncogene. 32:3443–3451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nawa T, Kato J, Kawamoto H, Okada H,
Yamamoto H, Kohno H, Endo H and Shiratori Y: Differences between
right- and left-sided colon cancer in patient characteristics,
cancer morphology and histology. J Gastroenterol Hepatol.
23:418–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rothberg PG, Spandorfer JM, Erisman MD,
Staroscik RN, Sears HF, Petersen RO and Astrin SM: Evidence that
c-myc expression defines two genetically distinct forms of
colorectal adenocarcinoma. Br J Cancer. 52:629–632. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gervaz P, Bouzourene H, Cerottini JP,
Chaubert P, Benhattar J, Secic M, Wexner S, Givel JC and Belin B:
Dukes B colorectal cancer: Distinct genetic categories and clinical
outcome based on proximal or distal tumor location. Dis Colon
Rectum. 44:364–372. 2001. View Article : Google Scholar : PubMed/NCBI
|
